Keros Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Keros Therapeutics Depreciation & Amortization Growth & History (KROS)
Keros Therapeutics's depreciation and amortization was $1.5M for fiscal 2025.
View full Keros Therapeutics company overviewKeros Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.5M | $280,000 | +22.78% |
| 2024 | 2024-12-31 | $1.2M | $414,000 | +50.80% |
| 2023 | 2023-12-31 | $815,000 | $141,000 | +20.92% |
| 2022 | 2022-12-31 | $674,000 | $296,000 | +78.31% |
| 2021 | 2021-12-31 | $378,000 | $100,000 | +35.97% |
| 2020 | 2020-12-31 | $278,000 | $70,000 | +33.65% |
| 2019 | 2019-12-31 | $208,000 | — | — |
Keros Therapeutics quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $402,000 | $32,000 | +8.65% |
| Q1 2026 | 2026-03-31 | $403,000 | $59,000 | +17.15% |
| Q4 2025 | 2025-12-31 | $400,000 | — | — |
| Q3 2025 | 2025-09-30 | $395,000 | $81,000 | +25.80% |
| Q2 2025 | 2025-06-30 | $370,000 | $64,000 | +20.92% |
| Q1 2025 | 2025-03-31 | $344,000 | $67,000 | +24.19% |
| Q3 2024 | 2024-09-30 | $314,000 | $104,000 | +49.52% |
| Q2 2024 | 2024-06-30 | $306,000 | $115,000 | +60.21% |
| Q1 2024 | 2024-03-31 | $277,000 | $110,000 | +65.87% |
| Q3 2023 | 2023-09-30 | $210,000 | $84,000 | +66.67% |
| Q2 2023 | 2023-06-30 | $191,000 | −$117,000 | −37.99% |
| Q1 2023 | 2023-03-31 | $167,000 | $54,000 | +47.79% |
| Q3 2022 | 2022-09-30 | $126,000 | $23,000 | +22.33% |
| Q2 2022 | 2022-06-30 | $308,000 | $217,000 | +238.46% |
| Q1 2022 | 2022-03-31 | $113,000 | $33,000 | +41.25% |
| Q3 2021 | 2021-09-30 | $103,000 | $31,000 | +43.06% |
| Q2 2021 | 2021-06-30 | $91,000 | $23,000 | +33.82% |
| Q1 2021 | 2021-03-31 | $80,000 | $17,000 | +26.98% |
| Q3 2020 | 2020-09-30 | $72,000 | $17,000 | +30.91% |
| Q2 2020 | 2020-06-30 | $68,000 | $19,000 | +38.78% |
| Q1 2020 | 2020-03-31 | $63,000 | $18,000 | +40.00% |
| Q3 2019 | 2019-09-30 | $55,000 | — | — |
| Q2 2019 | 2019-06-30 | $49,000 | — | — |
| Q1 2019 | 2019-03-31 | $45,000 | — | — |
Keros Therapeutics depreciation and amortization trends
Over the last five fiscal years, Keros Therapeutics's depreciation and amortization increased from $278,000 to $1.5M, a change of $1.2M. The latest reported quarter, Q2 2026, shows $402,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Keros Therapeutics source filings ↗